Live Roundups Editor's Desk Insights Executive Ops Weather About 🔍
Home › Health › Ozempic, Zepbound and other GLP-1 drugs have a possible...
Health

Ozempic, Zepbound and other GLP-1 drugs have a possible risk of vision loss

Ozempic, Zepbound and other GLP-1 drugs have a possible risk of vision loss
MarketWatch Monday 09 November 2026, 17:52 UTC By Jaimy Lee 1 min read
Key Points

Several medical studies have found that people taking GLP-1 medications have an elevated risk for nonarteritic anterior ischemic optic neuropathy, or NAION.

Several medical studies have found that people taking GLP-1 medications have an elevated risk for nonarteritic anterior ischemic optic neuropathy, or NAION.
Ozempic (ORG) Zepbound (PERSON) NAION (ORG)
Originally published by MarketWatch Read original →

Related Stories

Displaced families suffer in Gaza floods as 70,000 tents wrecked – video

Gaza's civil defence authorities declared a state of maximum emergency on Saturday as a rainstorm flooded about 70,000 tents housing displaced Palestinians and overwhelmed rescue services. The flooding has made daily life increasingly difficult for displaced families in the camps, now facing a third winter there after Israel's assault on Gaza. The authorities called on the international community to pressure Israel to allow the entry of specialised rescue equipment and vehicles, as well as...

The Guardian Health 7m ago

Supreme Court set to pare back federal inmates’s ability to sue officials

The Supreme Court on Monday appeared likely to bar prison inmates from suing officials who deny them medical treatment in the latest case seeking to roll back the ability to hold federal officials accountable for alleged constitutional violations. The court heard oral arguments over a claim brought by a former federal prison inmate, Kekai Watanabe, who alleges he was denied medical treatment by officers at a Honolulu-based facility in July 2021 after he was beaten by other prisoners during a...

NBC News 42m ago

US drug watchdog orders new safety warnings for weight-loss drugs over potential risk of vision loss

The US Food and Drug Administration (FDA) is requiring manufacturers of GLP-1 medicines to update their safety labels to warn of a potential increased risk of a rare but serious eye condition that can cause permanent vision loss. The US drug watchdog FDA on Monday said the weight-loss drugs had been associated with non-arteritic anterior ischaemic optic neuropathy (NAION), a condition that can lead to sudden, painless loss of vision in one eye, including permanent vision loss. The new...

Euronews 53m ago

Paramedic injured while assisting patient

The ambulance service said the "attack lasted a number of minutes"

BBC Health Extra 59m ago